{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:49:16Z","timestamp":1790686156420,"version":"4.1.0"},"reference-count":134,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardio-oncology, a burgeoning subspecialty, addresses the complex interplay between cardiology and oncology, particularly in light of increased cardiovascular (CV) disease mortality in cancer patients. This review provides a comprehensive overview of cardio-oncology with a focus on the therapies used in hematological malignancies. We explore the bidirectional relationship between heart failure and cancer, emphasizing the need for collaborative care. The review discusses risk stratification, highlighting the importance of baseline CV risk assessment and personalized surveillance regimens. Primary and secondary prevention strategies, including pharmacological interventions, are outlined. The review also delves into the cardiotoxicity associated with hematological cancer therapies, focusing on anthracyclines, Bruton kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, CAR-T cell therapy, immune checkpoint inhibitors, multiple myeloma treatments, and hematopoietic stem cell transplantation. We then highlight the high risk of venous and arterial thromboembolisms in cancer patients and the challenges of anticoagulation management in cardio-oncology. Finally, the review touches on the importance of long-term follow-up and appropriate screening in cancer survivors at high risk of CV morbidity and mortality, based on their CV risk profile and the type and dose of cardiotoxic therapies they received such as anthracyclines or high radiation doses.<\/jats:p>","DOI":"10.1055\/a-2284-5855","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T18:38:06Z","timestamp":1715279886000},"page":"255-267","source":"Crossref","is-referenced-by-count":7,"title":["Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology"],"prefix":"10.1055","volume":"44","author":[{"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"48","key":"ref1","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"K M Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"48","key":"ref2","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/eurheartj\/ehz781","article-title":"From trends to transformation: where cardio-oncology is to make a difference","volume":"40","author":"J Herrmann","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular Disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"S H Armenian","year":"2016","journal-title":"J Clin Oncol"},{"issue":"41","key":"ref4","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"A R Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","article-title":"Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: the Kaiser Permanente AYA Cancer Survivors study","volume":"34","author":"C Chao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaccao.2020.12.003","article-title":"Cardiovascular risk factors are associated with future cancer","volume":"3","author":"E S Lau","year":"2021","journal-title":"JACC Cardiooncol"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"e013754","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: cancer development in patients with cardiovascular disease","volume":"9","author":"J P Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"oead073","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: a systematic review and meta-analysis","volume":"3","author":"V Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"S Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/eurheartj\/ehz591","article-title":"Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation","volume":"41","author":"S Mas-Peiro","year":"2020","journal-title":"Eur Heart J"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00392-022-02135-7","article-title":"Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR","volume":"112","author":"S Mas-Peiro","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"e030603","DOI":"10.1161\/JAHA.123.030603","article-title":"Clonal hematopoiesis of indeterminate potential from a heart failure specialist's point of view","volume":"12","author":"M A Sikking","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations","volume":"42","author":"B Assmus","year":"2021","journal-title":"Eur Heart J"},{"issue":"7853","key":"ref14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","article-title":"The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis","volume":"592","author":"T P Fidler","year":"2021","journal-title":"Nature"},{"issue":"6327","key":"ref15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"J J Fuster","year":"2017","journal-title":"Science"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s44161-022-00154-1","article-title":"Clonal hematopoiesis, multi-omics and coronary artery disease","volume":"1","author":"T Nakao","year":"2022","journal-title":"Nat Cardiovasc Res"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"E C Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"A R Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"33","key":"ref19","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"K M Sanfilippo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","article-title":"Statins reduce mortality in multiple myeloma: a population-based US study","volume":"20","author":"A Afzal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"ref21","doi-asserted-by":"crossref","first-page":"e19596","DOI":"10.1097\/MD.0000000000019596","article-title":"Impact of statin use on cancer-specific mortality and recurrence: a meta-analysis of 60 observational studies","volume":"99","author":"J Yang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.numecd.2019.11.002","article-title":"Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015","volume":"30","author":"J Kim","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"32","key":"ref23","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/eurheartj\/ehab325","article-title":"Statin associated lower cancer risk and related mortality in patients with heart failure","volume":"42","author":"Q-W Ren","year":"2021","journal-title":"Eur Heart J"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"T G Neilan","year":"2023","journal-title":"JAMA"},{"issue":"33","key":"ref25","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"M Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11764-009-0110-5","article-title":"An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis","volume":"4","author":"R M Speck","year":"2010","journal-title":"J Cancer Surviv"},{"key":"ref28","first-page":"15","article-title":"The role of long-term physical activity in relation to cancer-related health outcomes: a 12-month follow-up of the Phys-Can RCT","volume":"22","author":"A-S Mazzoni","year":"2023","journal-title":"Integr Cancer Ther"},{"issue":"14","key":"ref29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"S H Armenian","year":"2018","journal-title":"Blood Adv"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"F A van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/bloodadvances.2023009839","article-title":"A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma","volume":"7","author":"A Arcari","year":"2023","journal-title":"Blood Adv"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","article-title":"Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie AGMT](NHL-14)","volume":"58","author":"M A Fridrik","year":"2016","journal-title":"Eur J Cancer"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1002\/cam4.5280","article-title":"The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma","volume":"12","author":"L Li","year":"2023","journal-title":"Cancer Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1060668","DOI":"10.3389\/fphar.2022.1060668","article-title":"Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: a systematic review and meta-analysis","volume":"13","author":"B Lu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hon.2764","article-title":"Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity","volume":"38","author":"L Rigacci","year":"2020","journal-title":"Hematol Oncol"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u226560 years: Results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"J-M Sancho","year":"2021","journal-title":"Cancer Med"},{"issue":"20","key":"ref37","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.3390\/cancers15205036","article-title":"Prospective, multicenter phase II trial of non-pegylated liposomal doxorubicin combined with ifosfamide in first-line treatment of advanced\/metastatic soft tissue sarcomas","volume":"15","author":"A Buonadonna","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/1471-2407-11-373","article-title":"Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial","volume":"11","author":"M Fiegl","year":"2011","journal-title":"BMC Cancer"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"S Luminari","year":"2018","journal-title":"Hematol Oncol"},{"issue":"05","key":"ref40","first-page":"970","article-title":"Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41409-020-01080-1","article-title":"Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation","volume":"56","author":"G H Oliveira","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"B Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17512433.2022.2106968","article-title":"Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"D Jiang","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"31","key":"ref44","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"J C Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"ref45","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"P Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"J P Sharman","year":"2020","journal-title":"Lancet"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"J R Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2023.41.16_suppl.7540","article-title":"A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)","volume":"41","author":"A Kittai","year":"2023","journal-title":"JCO"},{"issue":"03","key":"ref49","first-page":"100608","article-title":"Bleeding risk with antiplatelets and Bruton's tyrosine kinase inhibitors in patients with percutaneous coronary intervention","volume":"2","author":"A Mendez-Ruiz","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"13","key":"ref50","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2019.07.057","article-title":"Real-life insight into ibrutinib cardiovascular events: defining the loose ends","volume":"74","author":"J Bergler-Klein","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"ref51","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL","volume":"6","author":"F T Awan","year":"2022","journal-title":"Blood Adv"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"D Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood.V122.21.4017.4017","article-title":"Six-year follow-up of dasatinib-related pulmonary arterial hypertension (PAH) for chronic myeloid leukemia in single center","volume":"122","author":"Y-W Jeon","year":"2013","journal-title":"Blood"},{"issue":"15","key":"ref54","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"J J Moslehi","year":"2016","journal-title":"N Engl J Med"},{"issue":"35","key":"ref55","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"J J Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"J E Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"M C Barber","year":"2017","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"13","key":"ref58","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"J Herrmann","year":"2016","journal-title":"Circulation"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology Primer","volume":"4","author":"S Ganatra","year":"2022","journal-title":"JACC Cardiooncol"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"D W Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"ref61","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"S S Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"ref62","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"S J Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00277-019-03854-0","article-title":"Safety and efficacy of blinatumomab: a real world data","volume":"99","author":"A Apel","year":"2020","journal-title":"Ann Hematol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"S-H Jung","year":"2019","journal-title":"Ann Hematol"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"H Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"ref66","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"M S Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ejh.14088","article-title":"Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy","volume":"112","author":"N P Patel","year":"2024","journal-title":"Eur J Haematol"},{"issue":"25","key":"ref68","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"R M Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"101840","DOI":"10.1016\/j.jaccas.2023.101840","article-title":"CAR-T therapy in lymphoma patients with coexisting cardiomyopathy or cardiac lymphomatous involvement","volume":"15","author":"C T Ng","year":"2023","journal-title":"JACC Case Rep"},{"issue":"16","key":"ref70","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"D H Lee","year":"2023","journal-title":"Blood Adv"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"A K Ghosh","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"22","key":"ref72","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"S S Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s10238-023-01042-z","article-title":"Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis","volume":"23","author":"M Guo","year":"2023","journal-title":"Clin Exp Med"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"H Hatic","year":"2021","journal-title":"Ann Transl Med"},{"issue":"12","key":"ref75","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"D Y Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"ref76","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"J-E Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"J J Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"ref78","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"S S Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"ref79","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"D B Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"C Chen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"07","key":"ref81","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"C Anquetil","year":"2018","journal-title":"Circulation"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"2539493","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"M Fazel","year":"2019","journal-title":"Case Reports Immunol"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"C Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"16","key":"ref84","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"M D'Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"29","key":"ref85","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"D Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"ref86","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Z D Drobni","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"ref87","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"R Calabretta","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"ref88","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"L Zhang","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ehjacc\/zuac107","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias","volume":"11","author":"S A Gevaert","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"03","key":"ref90","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"A J Waxman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"ref91","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"D Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"05","key":"ref92","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.radonc.2020.08.007","article-title":"Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977-2005","volume":"152","author":"E Laugaard Lorenzen","year":"2020","journal-title":"Radiother Oncol"},{"issue":"04","key":"ref94","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaccao.2023.03.013","article-title":"Prediction of coronary heart disease events in blood or marrow transplantation recipients","volume":"5","author":"R Gangaraju","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"06","key":"ref95","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"A Vasbinder","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"10","key":"ref96","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"J F Timp","year":"2013","journal-title":"Blood"},{"issue":"23","key":"ref97","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"E Grilz","year":"2021","journal-title":"Eur Heart J"},{"issue":"14","key":"ref98","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/M17-0868","article-title":"Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data","volume":"167","author":"N van Es","year":"2017","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref100","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/jth.15001","article-title":"Risk scores for occult cancer in patients with unprovoked venous thromboembolism: results from an individual patient data meta-analysis","volume":"18","author":"F I Mulder","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"C Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2012.10.007","article-title":"Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry","volume":"131","author":"G Gussoni","year":"2013","journal-title":"Thromb Res"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.lanepe.2023.100739","article-title":"Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study","volume":"34","author":"H T S\u00f8rensen","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"03","key":"ref104","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1055\/s-0043-1770783","article-title":"Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding","volume":"7","author":"K S Caroti","year":"2023","journal-title":"TH Open"},{"issue":"22","key":"ref105","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"D Schrag","year":"2023","journal-title":"JAMA"},{"issue":"09","key":"ref106","first-page":"749","article-title":"Atrial fibrillation in active cancer patients: expert position paper and recommendations","volume":"72","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"10","key":"ref107","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1007\/s00520-022-07235-8","article-title":"Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)","volume":"30","author":"N Tsoukalas","year":"2022","journal-title":"Support Care Cancer"},{"issue":"12","key":"ref108","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.clinthera.2023.09.014","article-title":"Intensify standardized anticoagulation for cancer-associated pulmonary embolism: from single-center real-world data","volume":"45","author":"M Liu","year":"2023","journal-title":"Clin Ther"},{"issue":"09","key":"ref109","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic","volume":"16","author":"C E Holmes","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"07","key":"ref110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/rth2.12431","article-title":"Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis","volume":"4","author":"K A Martin","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref111","doi-asserted-by":"crossref","first-page":"102173","DOI":"10.1016\/j.rpth.2023.102173","article-title":"Venous thromboembolism prevention in cancer care: implementation strategies to address underuse","volume":"7","author":"K A Martin","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"ref112","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"D Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"issue":"16","key":"ref113","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref114","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"C Becattini","year":"2022","journal-title":"Blood"},{"issue":"06","key":"ref115","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial","volume":"3","author":"S R Guntupalli","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"ref116","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"08","key":"ref117","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref118","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref119","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"T-F Wang","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref120","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/cncr.34937","article-title":"Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents","volume":"129","author":"H Bolek","year":"2023","journal-title":"Cancer"},{"issue":"08","key":"ref121","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"B B Navi","year":"2019","journal-title":"Blood"},{"issue":"08","key":"ref122","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"B B Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref123","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3390\/cancers15113060","article-title":"Arterial thrombosis in patients with acute myeloid leukemia: incidence and risk factors","volume":"15","author":"M Mitrovic","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref124","first-page":"205","article-title":"Arterial thromboembolism in cancer patients: a Danish population-based cohort study","volume":"3","author":"F I Mulder","year":"2021","journal-title":"JACC Cardiooncol"},{"issue":"01","key":"ref125","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study","volume":"7","author":"C Ay","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"02","key":"ref126","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","article-title":"Arterial thromboembolism in patients with AF and CHA2DS2-VASc score 0-2 with and without cancer","volume":"5","author":"A Leader","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccao.2022.10.016","article-title":"Left atrial appendage occlusion in patients with atrial fibrillation and cancer","volume":"5","author":"S A Shabtaie","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"04","key":"ref128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaccao.2023.04.003","article-title":"Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: systematic review and meta-analysis","volume":"5","author":"Y Xu","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"09","key":"ref129","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"B Brenner","year":"2018","journal-title":"Am J Med"},{"issue":"04","key":"ref130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaccao.2023.05.006","article-title":"To anticoagulate or not to anticoagulate to prevent arterial thrombosis during systemic cancer therapy","volume":"5","author":"C Spaccarotella","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"03","key":"ref131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"D Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaccao.2022.12.007","article-title":"Screening for coronary artery disease in cancer survivors: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"R Velusamy","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"01","key":"ref133","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaccao.2022.12.001","article-title":"Cardio-oncology guidelines and strength of the evidence","volume":"5","author":"H Zheng","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"19","key":"ref134","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.3390\/ijms241914433","article-title":"Inhibition of factor XI: a new era in the treatment of venous thromboembolism in cancer patients?","volume":"24","author":"G Poenou","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2284-5855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:44:38Z","timestamp":1730807078000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2284-5855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":134,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2284-5855","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}